COVID-19 Detection Kits Market Trends & Forecast, 2026-2033

The test is designed to be user-friendly, allowing individuals to perform the test themselves in the comfort of their own homes. This self-testing option not only reduces the burden on healthcare systems but also promotes early identification of infected individuals, helping to prevent further spread of the virus in communities.

Figure 1.

COVID-19 DETECTION KITS MARKET

To learn more about this report, Download Free Sample

New technology introduction by the key players for the detection of new variant virus: The introduction of new technology for the detection of a new variant of the Corona virus brings hope for more accurate and efficient identification and containment measures. These advancements in technology have the potential to revolutionize the way we tackle the spread of infectious diseases. By providing quicker and more reliable results, we can promptly implement targeted interventions and minimize the impact on public health. For instance, on January 26, 2023, Bharat Biotech, a bio-therapeutics company, launched the world's first made-in-India intranasal vaccine. iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results. iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.

Figure 2.

COVID-19 DETECTION KITS MARKET

To learn more about this report, Download Free Sample

North America is estimated to hold 44% of the market share in 2026.

By product type,the market is segmented into RT-PCR assay kits and immunoassay test strips/cassettes.
By specimen type, the market is segmented into nasopharyngeal swab, oropharyngeal swab, nasal swab, sputum, and others. Out of which, nasopharyngeal swab is expected to dominate the market over the forecast period, and this is attributed to increasing patient choice for the testing.
By end user, the market is segmented into hospitals, diagnostic centers, and others. Out of which, diagnostic centers is expected to dominate the market over the forecast period, and this is attributed to an increase in the COVID test result for confirmation.

Report Coverage	Details
Base Year:	2025	Market Size in 2026:	USD 4.74 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	2.6%	2033 Value Projection:	USD 5.67 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: RT-PCR Assay Kits, Immunoassay Test Strips/Cassettes By Specimen Type: Nasopharyngeal swab, Oropharyngeal swab, Nasal swab, Sputum, Others By End User: Hospitals, Diagnostic centers, Others
Companies covered:	Co-Diagnostics, Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc., BioFire Diagnostics, GenMark Diagnostics, Qiagen, Quidel Corporation, Randox Laboratories Ltd., SD Biosensor, INC., Shenzhen Bioeasy Biotechnology Co., Ltd., Seegene Inc., JOYSBIO Biotechnology, Cipla Limited, Bione, Virax Biolabs Group Limited, SD BioSensor, Inc., NanoSpot.ai, J. Mitra & Co. Pvt. Ltd., Genes2Me, Ubio Biotechnology Systems Pvt Ltd, Bharat Biotech, Gennova Biopharmaceuticals, QRX Pharma, Angstrom Biotech Pvt. Ltd., and Detect, Inc.
Growth Drivers:
Restraints & Challenges:

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Key players, along with U.S. The vaccine, branded Gemcovac, was developed with funding from DBT and the Biotechnology Industry Research Assistance Council (BIRAC).

Therefore, now key players are not focusing on product development and the integration of new technology and methods to avoid the false-result issue.

Co-Diagnostics, Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc., BioFire Diagnostics, GenMark Diagnostics, Qiagen, Quidel Corporation, Randox Laboratories Ltd., SD Biosensor, INC., Shenzhen Bioeasy Biotechnology Co., Ltd., Seegene Inc., JOYSBIO Biotechnology, Cipla Limited, Bione, Virax Biolabs Group Limited, SD BioSensor, Inc., NanoSpot.ai, J. Mitra & Co. Pvt. Ltd., Genes2Me, Ubio Biotechnology Systems Pvt Ltd, Bharat Biotech, Gennova Biopharmaceuticals, QRX Pharma, Angstrom Biotech Pvt. Ltd., and Detect, Inc.

Sources

Primary Research Interviews

COVID-19 test kit manufacturers (e.g., Abbott, Roche Diagnostics, Siemens Healthineers, BD, Cepheid/Danaher, SD Biosensor)
Public health lab and clinical microbiology directors
FDA EUA and WHO EUL regulatory affairs teams

Databases

U.S. FDA EUA data
WHO EUL data
ECDC surveillance data

Magazines

CLP Magazine
MedTech Dive

Journals

Journal of Clinical Microbiology (ASM)
The Lancet Infectious Diseases

Newspapers

Reuters Health
Financial Times – Health

Associations

American Society for Microbiology (ASM)
Association for Molecular Pathology (AMP)
FIND (Foundation for Innovative New Diagnostics)

Public Domain Sources

U.S. FDA EUA database
WHO COVID-19 test data
ResearchGate publications on SARS-CoV-2 diagnostics

Proprietary Elements

CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years.

About Author

Nikhilesh Ravindra Patel is a Senior Consultant with over 8 years of consulting experience. He excels in market estimations, market insights, and identifying trends and opportunities. His deep understanding of the market dynamics and ability to pinpoint growth areas make him an invaluable asset in guiding clients toward informed business decisions. He plays a instrumental role in providing market intelligence, business intelligence, and competitive intelligence services through the reports.

Missing comfort of reading report in your local language? Find your preferred language :

Transform your Strategy with Exclusive Trending Reports :

Point Of Care Infectious Disease Diagnostics Market

Bone Degeneration Therapeutics Market

Constipation Treatment Market

Elbow Lesion Market

Oxygen Therapy Market

Companion Diagnostics Market

Frequently Asked Questions

The COVID-19 Detection Kits Market is estimated to be valued at USD 4.74 Bn in 2026, and is expected to reach USD 5.67 Bn by 2033.

The CAGR of the COVID-19 Detection Kits Market is projected to be 2.6% from 2026 to 2033.

The introduction of COVID-19 detection kits with advanced technology is expected to drive the market’s growth.

RT-PCR assay kits is the leading product type segment in the market.

False result by the COVID-19 detection kits is expected to hinder the market over the forecast period.

Major players operating in the market are Co-Diagnostics, Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc., BioFire Diagnostics, GenMark Diagnostics, Qiagen, Quidel Corporation, Randox Laboratories Ltd., SD Biosensor, INC., Shenzhen Bioeasy Biotechnology Co., Ltd., Seegene Inc., JOYSBIO Biotechnology, Cipla Limited, Bione, Virax Biolabs Group Limited, SD BioSensor, Inc., NanoSpot.ai, J. Mitra & Co. Pvt. Ltd., Genes2Me, Ubio Biotechnology Systems Pvt Ltd, Bharat Biotech, Gennova Biopharmaceuticals, QRX Pharma, Angstrom Biotech Pvt. Ltd., and Detect, Inc.